Flamel Technologies S.A. (ADR) (NASDAQ:FLML)

CAPS Rating: 3 out of 5

A biopharmaceutical company principally engaged in the development of two unique polymer-based drug delivery technologies for the improvement of medical applications.

Results 1 - 20 of 53 : 1 2 3 Next »

Recs

1
Member Avatar zzlangerhans (99.80) Submitted: 1/2/2016 9:40:30 PM : Outperform Start Price: $12.34 FLML Score: -17.34

Whenever I start thinking I screwed up absolutely every trade in 2015, I just go back and look at my Tweets on Flamel during the year. While my price points weren't ideal, I still managed to tranche trade the stock for strong profits and dumped my last bloc close to the year highs. Then I watched my Flamel profits remain solid near the top of the zzporte gains list as the stocks we held on to slipped into the swamp. I haven't trusted the stock since it plunged about 50% intraday on approval of a competitor's generic neostigmine a year ago. I bought on that dip and was lucky to escape when the stock rebounded, but my skepticism about long-term strength seems to have been well-founded. The latest smack to the stock came in the last trading session of the year, when the stock plummeted from 14's to 12 on word of approval of a second competing neostigmine generic.

The truth is, it is very difficult to model Flamel's future revenues from the Eclat generic pipeline, and their legacy Micropump/Medusa platform remains as dubious and opaque as ever. Flamel has a new PDUFA for an unspecified Eclat generic on April 26, and they've had a very good although not spotless record with the FDA thus far. That makes Flamel tempting for a new zzporte position given our prior success with the stock, but lately I've been trying to move away from positions at risk for surprising buzzcuts. In addition, our attempts to replicate prior successes with the same stocks haven't typically gone well. For that reason, I think Flamel is going to remain a CAPS-only play for the time being.

Recs

0
Member Avatar kaunas7 (23.54) Submitted: 4/28/2015 9:33:23 PM : Outperform Start Price: $14.50 FLML Score: -26.30

Starting to become very profitable and looking good for 2016 as well.

Recs

0
Member Avatar austinhippie (74.46) Submitted: 1/16/2015 5:11:09 PM : Outperform Start Price: $14.22 FLML Score: -28.57

$35/vial to $98/vial, nearly 10x rev increase this year over last expected.

Recs

0
Member Avatar MrMrr (< 20) Submitted: 7/1/2014 10:40:17 AM : Outperform Start Price: $14.88 FLML Score: -34.02

flml is the only one to have this new drug

Recs

1
Member Avatar phatchips767 (< 20) Submitted: 2/25/2014 5:34:00 PM : Outperform Start Price: $13.17 FLML Score: -32.60

french company. portofeille likeded em

Recs

1
Member Avatar ihletrader (< 20) Submitted: 1/22/2014 10:34:12 AM : Outperform Start Price: $10.33 FLML Score: -13.65

good perspective shared by ZZ.

Recs

0
Member Avatar line70day (< 20) Submitted: 10/28/2013 3:13:51 PM : Outperform Start Price: $7.24 FLML Score: +22.07

2nd Q FDA approved NDA first approval for drugs that will be 100% controlled by Flamel This is first filling that came out of Eclat's pipeline 3 more products steadly advancing

Recs

0
Member Avatar KimLanners (< 20) Submitted: 4/24/2011 2:15:52 AM : Outperform Start Price: $6.20 FLML Score: +6.36

nanobiotech good technicals

Recs

0
Member Avatar face2thehighfog (65.39) Submitted: 9/18/2009 10:38:47 AM : Outperform Start Price: $9.55 FLML Score: -80.08

nano!

Recs

0
Member Avatar AAAAmanda (61.91) Submitted: 2/2/2009 2:37:12 PM : Outperform Start Price: $4.19 FLML Score: -15.65

5.1172 at $111.00 or 21.69 per share. Can't do much worse.

Recs

0
Member Avatar zoiebelle (66.82) Submitted: 6/4/2008 10:10:50 PM : Outperform Start Price: $10.45 FLML Score: -52.88

Niche in medical technology will pay off.

Recs

0
Member Avatar WERDOSD44 (72.11) Submitted: 3/24/2008 4:17:03 PM : Outperform Start Price: $8.96 FLML Score: -42.51

THIS STOCK HAS BEEN AT $31.96, BELIEVE ITS ON ITS WAY TO THAT AREA AGAIN

Recs

0
Member Avatar gdufour (42.67) Submitted: 1/16/2008 5:50:39 AM : Outperform Start Price: $9.40 FLML Score: -45.32

Never stays above 30, but surely gets there every now and then, so at a price below 10, this is a good bargain.

Recs

0
Member Avatar nmhiplains (49.85) Submitted: 1/14/2008 10:07:03 PM : Outperform Start Price: $9.54 FLML Score: -44.27

Drug release procall for insulin

Recs

0
Member Avatar taryntoo (< 20) Submitted: 12/26/2007 12:14:19 AM : Outperform Start Price: $10.70 FLML Score: -46.26

Bought at the bottom of their 52 week range. Not sure even that price is justified, but hoping their delivery technology will find new markets.

Recs

0
Member Avatar PicoTrader (< 20) Submitted: 10/19/2007 1:14:42 PM : Outperform Start Price: $8.15 FLML Score: -18.01

purely a play on the fallen who should get up, even if its to a crawling position....

Recs

0
Member Avatar lowmaple (< 20) Submitted: 10/19/2007 2:01:20 AM : Outperform Start Price: $9.10 FLML Score: -28.27

rebound

Recs

0
Member Avatar scrubs620 (< 20) Submitted: 9/12/2007 8:01:25 PM : Outperform Start Price: $9.95 FLML Score: -41.30

New license with Wyeth for the use of its protein delivery system.

Recs

0
Member Avatar miralooku (< 20) Submitted: 9/8/2007 5:55:35 AM : Outperform Start Price: $9.14 FLML Score: -35.06

Powerful technology, activist investors, and 52-low price adds up to a market over-reaction. Buy now sit back, and enjoy the ride. This will return at least 50% in the next year or so.

Recs

0
Member Avatar tharlow (71.35) Submitted: 8/30/2007 8:10:48 AM : Outperform Start Price: $9.52 FLML Score: -40.00

The French are now our friends.

Results 1 - 20 of 53 : 1 2 3 Next »

Featured Broker Partners